Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antipsychotic medication |
| gptkbp:approvedBy |
1996 (Europe)
|
| gptkbp:ATCCode |
N05AE03
|
| gptkbp:CASNumber |
106516-24-9
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Lundbeck
|
| gptkbp:eliminationHalfLife |
2-3 days
|
| gptkbp:hasMolecularFormula |
C24H26ClFN4O
|
| https://www.w3.org/2000/01/rdf-schema#label |
sertindole
|
| gptkbp:IUPACName |
1-[2-[4-[5-chloro-1-(4-fluorophenyl)indol-3-yl]piperidin-1-yl]ethyl]imidazolidin-2-one
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
alpha-1 adrenergic receptor antagonist serotonin 5-HT2 receptor antagonist |
| gptkbp:proteinBinding |
~99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
weight gain QT prolongation drowsiness sexual dysfunction |
| gptkbp:usedFor |
treatment of schizophrenia
|
| gptkbp:bfsParent |
gptkb:N05AX
gptkb:KCNH2 gptkb:5-HT2C_receptor |
| gptkbp:bfsLayer |
7
|